Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

November 30, 2008

Study Completion Date

November 30, 2008

Conditions
Anti-p53 TCR-Gene
Interventions
BIOLOGICAL

anti-protein 53 or tumor protein 53 (p53) T-cell receptor transduced peripheral blood lymphocytes

Peripheral blood lymphocytes are harvested by lymphapheresis and engineered to express a T cell receptor that binds to P53.

BIOLOGICAL

aldesleukin

720,000 IU/kg intravenously over 15 minutes every 8 hours for up to 5 days

BIOLOGICAL

filgrastim

Beginning on day 1 or 2, administered subcutaneously at a dose of 5 mcg/kg/day (not to exceed 300 mcg/day); continue daily until neutrophil count \> 1.0 x 10\^9/L x 3 days or \> 5.0 x 10\^9/L.

DRUG

cyclophosphamide

60 mg/kg/day x 2 days intravenously in 250ml dextrose 5% in water (D5W) with mesna 15 mg/kg/day x 2 days over 1 hour.

DRUG

fludarabine phosphate

25 mg/m2/day intravenously piggyback (IVPB) daily over 30 minutes for 5 days.

Trial Locations (1)

20892

National Institutes of Health, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00393029 - Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes | Biotech Hunter | Biotech Hunter